TCGX SEC Filings, Earnings & Splits

TCGX Acquisition Corp. entered into a Business Combination Agreement with TriGemX Bio, Inc. (formerly Kallyope, Inc.), under which TCGX will domesticate to Delaware and merge with TriGemX, with TriGemX surviving as a wholly-owned subsidiary. The deal values TriGemX at a pre-money equity value of $361 million and is expected to close in Q1 2027.

RA Capital Management, Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund filed a joint filing agreement regarding their beneficial ownership of TCGX Acquisition Corp. Class A Ordinary Shares. The agreement allows them to file a single Schedule 13G/13D on behalf of all parties.

Biotechnology Value Fund entities and Mark N. Lampert filed a Schedule 13G joint filing agreement regarding their beneficial ownership of Class A ordinary shares of TCGX Acquisition Corp. The filing indicates passive ownership by the BVF group.